Cubit Diagnostics today announced it has closed its latest round of SAFE (Simple Agreement for Future Equity) financing. The proceeds will fund the company's next phase of work, centered on locking in ...

Potency assay development uses DoE and QbD to improve accuracy, consistency, and regulatory readiness in biologics testing.

Cloud-Clone has built an integrated antibody R&D and manufacturing platform, focusing on enhancing product consistency and MP for research and diagnostics. HUSTON, TX, UNITED STAT ...

A new Armatus publication summarizes a novel potency assay platform to advance gene silencing therapies for rare neuromuscular diseases.

Chantle Edillor used a fascination with sourdough starters to pivot from studying human diseases to exploring yeast-based ...

New service offering enables GR/NF-κB transrepression studies to support deeper mechanism-of-action insight in drug ...

When this is done well, biomarkers accelerate decision-making, reduce uncertainty, and ultimately bring improved therapies to patients faster. When this is done poorly, however, biomarkers can add ...

The oral presentation, titled, “¹⁸⁶Rhenium-Nanoliposomes (¹⁸⁶RNL) for the Treatment of Leptomeningeal Metastases: Translational Insights from Clinical and Preclinical Models,” was delivered by ...

Discusses BGE-102 Clinical Results and Development Strategy for Cardiovascular and Retinal Disease May 8, 2026 12:30 PM ...

Aberdeen Proving Ground, MD – Trainers at the U.S. Army Combat Capabilities Development Command Chemical Biological Center ...

Assay results from 14 drill holes (3,500m; ~10% of planned in-fill drilling) have been received, with notable results ...

LiquidCell Dx, a next generation cancer diagnostics company, today announced publication in Nature of critical research underpinning the development of LiquidTME, its blood-based assay for tumor ...